Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

Cholinergic Antagonists: Pharmacokinetics

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Nursing Interventions II: Selecting and Classifying the Nursing Interventions

Nursing Interventions II: Selecting and Classifying the Nursing Interventions

Creating and executing a nursing diagnosis helps nurses plan care and guide patient, family, and community interventions. They are developed based on a patient's physical evaluation and support measuring the outcomes. It is not recommended to select random interventions throughout the planning process. Instead, consider the following six essential factors when choosing interventions:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Thermal Ablation with or without Liver Transplantation for Hepatocellular Carcinoma in Older Adults with Child-Pugh Class A Cirrhosis.

Journal of vascular and interventional radiology : JVIR·2026

Same author

Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome type 1.

JCEM case reports·2026

Same author

Refractory Ascites and the Alfapump.

Gastro hep advances·2026

Same author

HCC Metastasis to the Sigmoid Colon and Rectum.

ACG case reports journal·2026

Same author

Gastroenterologist's Guide to Assess for Alcohol Use.

Digestive diseases and sciences·2026

Same author

Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same journal

Colorectal Cancer Outcomes Among Disaggregated Asian Subgroups: a 2006-2020 SEER Analysis.

Digestive diseases and sciences·2026

Same journal

Longitudinal Ulcer: Esophageal Tuberculosis Masquerading as Esophageal Crohn's Disease.

Digestive diseases and sciences·2026

Same journal

Effects of Abnormal Lipid Metabolism on Pancreatic Injury and Ferroptosis-Related Indicators in Rats with Severe Acute Pancreatitis.

Digestive diseases and sciences·2026

Same journal

Genetic Analysis of Isolated Hepatic Ductal Plate Malformation Reveals Novel Variants and Insights into Phenotypic Correlation.

Digestive diseases and sciences·2026

Same journal

Disease Burden of Early-Onset Pancreatic Cancer in Adults Aged 20-54 Years in Low- and Middle-Income Countries: A GBD 2023 Analysis.

Digestive diseases and sciences·2026

Same journal

Patient Perspectives of Intestinal Ultrasound in IBD: A Quantitative Evaluation of Satisfaction and Diagnostic Preference.

Digestive diseases and sciences·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Use of Micropipette-Guided Drug Administration as an Alternative Method to Oral Gavage in Rodent Models

Use of Micropipette-Guided Drug Administration as an Alternative Method to Oral Gavage in Rodent Models

Published on: July 26, 2024

Selecting Pharmacologic Interventions for MASH.

Jason J Pan^1,2, Brian H Horwich¹, Mohamad Chahine¹

¹Departments of Surgery and Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Digestive Diseases and Sciences

|June 17, 2026

Summary

This summary is machine-generated.

Two new FDA-approved MASH treatments, resmetirom and semaglutide, offer options for advanced liver fibrosis. This review compares their benefits, side effects, and contraindications to guide clinical selection.

Keywords:

MASH NASH Pharmacological treatments Steatosis Steatotic Liver Disease

Related Experiment Videos

Last Updated: Jun 18, 2026

Use of Micropipette-Guided Drug Administration as an Alternative Method to Oral Gavage in Rodent Models

Use of Micropipette-Guided Drug Administration as an Alternative Method to Oral Gavage in Rodent Models

Published on: July 26, 2024

Area of Science:

Hepatology
Pharmacology
Metabolic Disorders

Background:

Metabolic dysfunction-associated steatohepatitis (MASH) is a leading cause of cirrhosis and hepatocellular carcinoma.
Advanced hepatic fibrosis due to MASH is a growing indication for liver transplantation.
Recent FDA approvals offer new therapeutic avenues for MASH.

Purpose of the Study:

To compare the clinical benefits, contraindications, and side effects of resmetirom and semaglutide.
To provide a framework for individualizing MASH treatment selection.
To analyze pivotal data from the MAESTRO-NASH and ESSENCE trials.

Main Methods:

Comparative analysis of pivotal trial data (MAESTRO-NASH and ESSENCE).
Review of pharmacological profiles and clinical outcomes for resmetirom and semaglutide.
Evaluation of safety and efficacy data for MASH treatment.

Main Results:

Resmetirom (thyroid hormone receptor-β agonist) reduces steatohepatitis and fibrosis, improving lipids.
Semaglutide (GLP-1 receptor agonist) shows efficacy in MASH and fibrosis, with cardiometabolic benefits.
Both agents are now considered first-line for MASH with advanced fibrosis, necessitating careful selection.

Conclusions:

Clinicians must navigate the choice between resmetirom and semaglutide based on individual patient profiles.
Understanding the distinct mechanisms and trial outcomes is crucial for optimal MASH management.
This review aids in personalized treatment strategies for MASH patients with moderate-to-advanced fibrosis.